Project description
An innovative tissue processor for fast diagnosis
Tissue processing is a laborious procedure that takes up to 24 h and uses harmful chemicals. The key objective of the EU-funded Origin project is to bring to the market an innovative device that reduces the number of processing steps and chemicals used. Importantly, chemical waste can be disposed of in an environmentally friendly way, and the device is less expensive to operate. The project will undertake the necessary activities for validating and further optimising the device beyond the prototype stage to deliver faster diagnosis and results in a clinical setting.
Objective
Current tissue processors on the market take up to 24 hours to process samples for diagnosis and leave the operator exposed to chemical fumes. They also use different kinds of chemicals, in large volumes, which leads to cross contamination of chemicals and samples. This results in more plastic packaging to dispose of, making the process both costly and environmental unfriendly. Our company, DIAPATH SpA, is developing an innovative solution to these problems - the E-Processor. DIAPATH has been in the tissue processing industry since 1997 and currently has a turnover of €12Million and 100 employees. The E-Processor reduces the number of processing steps, and reduces the number of chemicals used. The operator will be safeguarded from chemical fumes and chemical containers will now be disposed of in a safe and environmentally friendly way. Our value proposition is, less operating costs due to reduced chemicals and packaging, faster diagnosis and results for patients. Our target users are Hospitals and Diagnostics Laboratories. The current global diagnostics market is estimated at €243.59 Million and expected to reach €378 Million by year 2025. Our entry point for our innovation will be the European market, where we already have significant market share. We will be using our extensive distribution chain to bring our innovation to international markets. Our innovation is currently at prototype stage with a compact functional machine. Further validation and tests remain to be done to bring it to market. The purpose of the phase 1 is to carry out feasibility studies before commercialisation. This will allow us to come up with a detailed business plan covering a projected five-year period. This innovation will grow our market share from 30% and increase our turnover to €50million by 2023. It will also create 15 new jobs.
Fields of science
- engineering and technologyenvironmental engineeringwaste management
- social scienceseconomics and businesseconomicsproduction economicsproductivity
- medical and health sciencesclinical medicineoncology
- natural scienceschemical sciencesorganic chemistryalcohols
- natural sciencescomputer and information sciencesartificial intelligencemachine learningdeep learning
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
24057 Martinengo (Bg)
Italy
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.